Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/27844
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKamitaki, Brad K-
dc.contributor.authorJanmohamed, Mubeen-
dc.contributor.authorKandula, Padmaja-
dc.contributor.authorElder, Christopher-
dc.contributor.authorMani, Ram-
dc.contributor.authorWong, Stephen-
dc.contributor.authorPerucca, Piero-
dc.contributor.authorO'Brien, Terence J-
dc.contributor.authorLin, Haiqun-
dc.contributor.authorHeiman, Gary A-
dc.contributor.authorChoi, Hyunmi-
dc.date2021-10-27-
dc.date.accessioned2021-11-03T00:34:54Z-
dc.date.available2021-11-03T00:34:54Z-
dc.date.issued2021-10-27-
dc.identifier.citationEpilepsia 2022; 63(1): 150-161en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/27844-
dc.description.abstractWe sought to determine which combination of clinical and electroencephalography (EEG) characteristics differentiate between an antiseizure medication (ASM)-resistant vs ASM-responsive outcome for patients with idiopathic generalized epilepsy (IGE). This was a case-control study of ASM-resistant cases and ASM-responsive controls with IGE treated at five epilepsy centers in the United States and Australia between 2002 and 2018. We recorded clinical characteristics and findings from the first available EEG study for each patient. We then compared characteristics of cases vs controls using multivariable logistic regression to develop a predictive model of ASM-resistant IGE. We identified 118 ASM-resistant cases and 114 ASM-responsive controls with IGE. First, we confirmed our recent finding that catamenial epilepsy is associated with ASM-resistant IGE (odds ratio [OR] 3.53, 95% confidence interval [CI] 1.32-10.41, for all study subjects) after covariate adjustment. Other independent factors seen with ASM resistance include certain seizure-type combinations (absence, myoclonic, and generalized tonic-clonic seizures [OR 7.06, 95% CI 2.55-20.96]; absence and generalized tonic-clonic seizures [OR 4.45, 95% CI 1.84-11.34]), as well as EEG markers of increased generalized spike-wave discharges (GSWs) in sleep (OR 3.43, 95% CI 1.12-11.36 for frequent and OR 7.21, 95% CI 1.50-54.07 for abundant discharges in sleep) and the presence of generalized polyspike trains (GPTs; OR 5.49, 95% CI 1.27-38.69). The discriminative ability of our final multivariable model, as measured by area under the receiver-operating characteristic curve, was 0.80. Multiple clinical and EEG characteristics independently predict ASM resistance in IGE. To improve understanding of a patient's prognosis, clinicians could consider asking about specific seizure-type combinations and track whether they experience catamenial epilepsy. Obtaining prolonged EEG studies to record the burden of GSWs in sleep and assessing for the presence of GPTs may provide additional predictive value.en
dc.language.isoeng-
dc.subjectcase-control studyen
dc.subjectcatamenialen
dc.subjectepidemiologyen
dc.subjectoutcomeen
dc.subjectprognosisen
dc.titleClinical and EEG factors associated with antiseizure medication resistance in idiopathic generalized epilepsy.en
dc.typeJournal Articleen
dc.identifier.journaltitleEpilepsiaen
dc.identifier.affiliationComprehensive Epilepsy Programen
dc.identifier.affiliationDepartment of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USAen
dc.identifier.affiliationDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australiaen
dc.identifier.affiliationNeurology Department, Alfred Hospital, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartments of Medicine and Neurology, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Neurology, Cornell University, New York, NY, USAen
dc.identifier.affiliationDepartment of Neurology, Columbia University, New York, New York, USAen
dc.identifier.affiliationDepartment of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USAen
dc.identifier.affiliationSchool of Nursing, Rutgers, the State University of New Jersey, Newark, New Jersey, USAen
dc.identifier.affiliationDepartment of Genetics, Human Genetics Institute of New Jersey, Rutgers, the State University of New Jersey, Piscataway, New Jersey, USAen
dc.identifier.affiliationDepartment of Neurology, Columbia University, New York, New York, USAen
dc.identifier.affiliationMedicine (University of Melbourne)en
dc.identifier.doi10.1111/epi.17104en
dc.type.contentTexten
dc.identifier.orcid0000-0001-7600-7805en
dc.identifier.orcid0000-0001-8601-3686en
dc.identifier.orcid0000-0002-7855-7066en
dc.identifier.orcid0000-0001-5859-0259en
dc.identifier.orcid0000-0002-0826-2350en
dc.identifier.pubmedid34705264-
local.name.researcherPerucca, Piero
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptNeurology-
crisitem.author.deptComprehensive Epilepsy Program-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

40
checked on Nov 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.